Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies

SIMPLE SUMMARY: Glioma is the most common primary intracranial tumor.Glioma involves a wide variety of cells and is highly aggressive, so most patients with glioblastoma have a poor prognosis.Glioma involves a wide variety of cells and is highly aggressive, so most patients with glioblastoma have a poor prognosis. CRISPR/Cas9 has the property of precise localization, and more and more studies focus on using it for the treatment of glioma and the exploration of its pathogenesis.This paper mainly discusses the role of CRISPR/Cas9 in the treatment of glioma patients, screening of key targets for clinical prognosis, and exploring the pathogenesis of glioma.The future research prospects of CRISPR/Cas9 in glioma treatment and potential opportunities and challenges are also pointed out. In order to help readers comprehensively understand the application and development of CRISPR/Cas9 in glioma research. ABSTRACT: Glioma refers to a tumor that is derived from brain glial stem cells or progenitor cells and is the most common primary intracranial tumor. Due to its complex cellular components, as well as the aggressiveness and specificity of the pathogenic site of glioma, most patients with malignant glioma have poor prognoses following surgeries, radiotherapies, and chemotherapies. In recent years, an increasing amount of research has focused on the use of CRISPR/Cas9 gene-editing technology in the treatment of glioma. As an emerging gene-editing technology, CRISPR/Cas9 utilizes the expression of certain functional proteins to repair tissues or treat gene-deficient diseases and could be applied to immunotherapies through the expression of antigens, antibodies, or receptors. In addition, some research also utilized CRISPR/Cas9 to establish tumor models so as to study tumor pathogenesis and screen tumor prognostic targets. This paper mainly discusses the roles of CRISPR/Cas9 in the treatment of glioma patients, the exploration of the pathogenesis of neuroglioma, and the screening targets for clinical prognosis. This paper also raises the future research prospects of CRISPR/Cas9 in glioma, as well as the opportunities and challenges that it will face in clinical treatment in the future.